The aim of this study was to investigate the impact of occurrence of chronic GVHD (cGVHD) and its severity on transplantation outcomes in a consecutive cohort of AML and myelodysplastic syndrome (MDS) patients who received unmanipulated haploidentical hematopoietic SCT (haplo-HSCT; n = 324). The cumulative incidence of relapse was significantly decreased in patients with cGVHD compared with the non-cGVHD group (1 year: 3.2% vs 11.9%, P = 0.002; 3 years: 6.0% vs 16.3%, P = 0.002), particularly in those with mild cGVHD. The cumulative incidence of non-relapse mortality was comparable between patients with and without cGVHD. The probabilities of disease-free survival (DFS) were significantly better in patients with cGVHD than in those in the non-cGVHD group (1 year: 90.5% vs 78.5%, P = 0.002; 3 years: 86.5% vs 71.5%, Po 0.001), particularly in those with mild or moderate cGVHD; however, no significant impact of severe cGVHD on DFS was seen. Our findings highlight the close relationship between cGVHD and the immune-mediated GVL effect in patients with AML and MDS receiving unmanipulated haplo-HSCT; however, only mild or moderate cGVHD was associated with a lower risk of relapse translating into improved DFS.
INTRODUCTION
Immune-mediated GVL is considered to be one of the most critical mechanisms for the reduction of relapse risk after allogeneic hematopoietic SCT (HSCT). Previous observations correlated disease control with the occurrence of chronic GVHD (cGVHD), suggesting that cGVHD may be associated with GVL effects. However, many patients in these studies received HSCT for CML that is much more susceptible to GVL mechanisms. 1 In AML and myelodysplastic syndrome (MDS) patients, the antineoplastic potency of cGVHD is still controversial. Sullivan et al. 2 observed that among AML patients in CR, cGVHD had an adverse effect on survival and no apparent influence on relapse. Weisdorf et al. 3 noted that after myeloablative conditioning, cGVHD had an adverse effect on non-relapse mortality (NRM) with an early modest augmentation of GVHD-associated GVL. Furthermore, treatment failure and survival risks were similar in patients with and without cGVHD. In a study by Baron et al., 4 cGVHD was associated with a lower risk of relapse; however, only limited cGVHD improved survival, which suggested that regulating the severity of cGVHD, and maintaining the balance between relapse and NRM, was critical for disease-free survival (DFS) after HSCT. Nevertheless, most of these studies used the Seattle Staging System that categorizes episodes of cGVHD as 'limited' or 'extensive', and these criteria lack sufficient information regarding the severity of cGVHD and the degree of functional impairment. 5 In 2005, the National Institutes of Health (NIH) Consensus Conference proposed a new set of criteria for the diagnosis and clinical scoring of cGVHD. 6 Using this composite score in addition to the number of organs or sites involved, a new global scoring system was proposed for assessing cGVHD severity. Subsequently, several studies observed that NIH global scoring was useful for predicting NRM and GVHD-specific survival. 7, 8 However, relatively few reports have examined the association between NIH global scoring and either relapse or DFS after HSCT.
An HLA haploidentical related donor is one of the most important alternative sources of stem cells for patients without matched donors. In recent years, much progress has been made in haploidentical HSCT (haplo-HSCT), 9, 10 and its clinical outcomes have been reported to be comparable to those of HLA-identical sibling donor or HLA-matched unrelated donor HSCT. 11, 12 Although cGVHD is common after haplo-HSCT, it is unclear whether cGVHD is associated with a lower incidence of leukemia relapse due to GVL effects.
Therefore, the present study aims to investigate the impact of occurrence of cGVHD and its severity on transplantation outcomes in a consecutive cohort of AML and MDS patients who received unmanipulated haplo-HSCT.
MATERIALS AND METHODS Patients
This study included all consecutive patients who underwent unmanipulated haplo-HSCT for AML (CR1 or CR2) or MDS (refractory anemia with excess blasts, RAEB1 or RAEB2) at the Institute of Hematology, Peking University, Beijing, China, between January 2006 and December 2011. Patients who had positive minimal residual disease and received interventional DLI after transplantation were excluded (n = 22). The final study cohort comprised of 324 patients ( Table 1 ). The last follow-up visits for end point analysis were conducted in January 2014. Informed consent was obtained from all patients and the study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the ethics committee of Peking University People's Hospital. One hundred and fifteen patients were previously reported in 2013, 13 and all of these were enrolled and followed further in this study.
Transplant regimens
The preconditioning treatment consisted of cytarabine (4 g/m 2 per day for 2 days), BU (4 mg/kg per day administered orally for 3 days before January 2008 or 3.2 mg/kg per day administered i.v. for 3 days after January 2008), CY (1.8 g/m 2 per day for 2 days) and simustine (250 mg/m 2 for 1 day), along with rabbit anti-thymocyte globulin (ATG; thymoglobulin; rabbit anti-thymocyte globulin from Imtix Sangstat, Lyon, France; 2.5 mg/kg per day for 4 days). All of the patients received G-CSF-mobilized, fresh and unmanipulated BM (G-BM) cells plus PBSCs (G-PB). G-CSF (5-10 μg/kg per day, injected s.c.) was provided to all of the recipients from day 6 after transplantation until their WBC count exceeded 2 × 10 9 cells/L for three consecutive days. In addition, all patients received CsA, mycophenolate mofetil and short-term MTX for GVHD prophylaxis. 14, 15 Donor selection and HLA typing
Patients without a suitable closely matched unrelated donor, namely, with 48 of 10 matching HLA-A, B, C, DR and DQ loci, and 5 of 6 or 6 of 6 matching HLA-A, B and DR loci, were eligible for haplo-HSCT if an identical sibling donor was unavailable as a first treatment option. To determine HLA-A and B status, low-resolution DNA techniques were used. Highresolution techniques were used for HLA-DRB1 typing. Each patient with haploidentical related donor received stem cells from a family member who shared 1 HLA haplotype with the patient but differed to a variable degree for the HLA-A, B, and D of the haplotype not shared. Apart from each donor recipient pair, HLA typing was performed for parents and offspring to be strictly analyzed to guarantee true haploid genetic background. 15 Diagnosis and global scoring of cGVHD Diagnosis of cGVHD was in accordance with the NIH consensus criteria. 6 cGVHD was diagnosed whether the patient presented at least one diagnostic clinical sign of cGVHD or at least one distinctive manifestation confirmed by pertinent biopsy or other relevant tests and exclusion of any other possible diagnosis. Mild cGVHD was one or two organs (except the lung) with score 1. Moderate cGVHD was three or more organs with score 1 or the lung score 1, or one or more organs with score 2. Severe cGVHD was any organ with score 3 or lung score 2. 6 Definitions and assessments Cytogenetic risks were assessed and classified into three risk groups (good, intermediate and poor) according to the criteria of the Southwest Oncology Group/Eastern Cooperative Oncology Group for patients diagnosed with AML and the criteria of the International Prognostic Scoring System for patients diagnosed with MDS. 16, 17 The incidence of comorbidities in HSCT recipients was assessed based on the hematopoietic cell transplantation-specific comorbidity index. 18 Relapse was defined by morphologic evidence of disease in samples from the PBL, BM or extramedullary sites, or by the recurrence and sustained presence of pre-transplantation chromosomal abnormalities. Patients who showed minimal residual disease were not classified as having relapsed. NRM was defined as death after HSCT without disease progression or relapse. DFS was defined as the survival period with continuous CR.
Statistical analysis
Data were censored at the time of relapse, NRM or last available follow-up. Demographic and clinical characteristics were compared between the cGVHD and non-cGVHD groups by using χ 2 and Fisher's exact tests for dichotomous variables and the Mann-Whitney U-test for continuous variables. Survival probabilities were estimated using the Kaplan-Meier method. Competing risk analysis was performed to calculate the cumulative incidence of cGVHD, relapse and NRM, and Gray's test was used to examine the differences between the cGVHD and non-cGVHD groups. 19 Death without GVHD was the competing event for GVHD. For NRM, relapse was the competing event, and for relapse, NRM was the competing event. Multivariate hazard ratios (HRs) for DFS were estimated from Cox proportional hazards regression, whereas the Fine and Gray's proportional hazards model for subdistribution of a competing risk was used to estimate the multivariate HRs for relapse and NRM. 20 Factors included in the regression model were age, gender, underlying disease, intermediate/poor cytogenetics, disease status at transplantation, HLA disparity (1 locus vs ⩾ 2 loci), donor-recipient gender matching (femalemale vs others), ABO compatibility, hematopoietic cell transplantation- Impact of cGVHD on relapse The 1-and 3-year cumulative incidences of relapse were significantly decreased in patients with cGVHD compared with the non-cGVHD group (1 year: 3.2% vs 11.9%, P = 0.002; 3 years: 6.0% vs 16.3%, P = 0.002), particularly in those with mild cGVHD (Figures 1a-d) . In multivariate analysis, the occurrence of mild cGVHD was associated with a significantly lower risk of relapse (1 Impact of cGVHD on NRM Causes of NRM were described in Table 2 . The 1-and 3-year cumulative incidences of NRM were comparable between the cGVHD and non-cGVHD groups (1 year: 6.3% vs 9.6%, P = 0.256; Impact of cGVHD on DFS The 1-and 3-year probabilities of DFS were significantly better in patients with cGVHD than those in the non-cGVHD group (1 year: 90.5% vs 78.5%, P = 0.002; 3 years: 86.5% vs 71.5%, Po 0.001), particularly in those with mild or moderate cGVHD (Figures 3a-d) . In multivariate analysis, occurrence of mild (1 
DISCUSSION
Although several studies have observed that cGVHD, which is closely related to the GVL effect, can decrease the risk of relapse after allogeneic HSCT, most of them enrolled the matched unrelated donor or identical sibling donor HSCT recipients. [2] [3] [4] Thus, the association between the severity of cGVHD and either relapse or DFS after unmanipulated haplo-HSCT is unclear. In our study, the positive impact of cGVHD on relapse and DFS, (that is, lower risk of relapse translating into better DFS) demonstrated the susceptibility of AML and MDS to the GVL effect; however, the beneficial effect of cGVHD in terms of survival was restricted to patients with mild or moderate cGVHD. Thus, our first observation was that the severity of cGVHD had a significant impact on transplantation outcomes in patients who received unmanipulated haplo-HSCT for AML and MDS. The idea that severe cGVHD can improve survival through decrease of relapse is still controversial. Terwey et al. 21 reported that cGVHD of any grade was associated with superior overall survival owing to the lower relapse incidence and no significant impact of cGVHD on NRM was seen. However, although relapse was uncommon after the development of cGVHD (8-9%), Lee et al. 22 could find no evidence that the relapse rate was associated with cGVHD severity and increasing severity of cGVHD was not associated with a longer time to relapse. Baron et al. 4 and Abbreviations: cGVHD = chronic GVHD; HSCT = hematopoietic SCT. Signori et al. 23 observed that only limited cGVHD was associated with lower relapse rates and improved survival. Saillard et al. 24 found that mild and moderate cGVHD, diagnosed on the basis of the NIH criteria, were associated with better survival than the severe form owing to the higher NRM among the latter patients, although they had a comparable relapse risk. We observed that mild and moderate cGVHD was associated with significantly improved DFS; however, no significant impact of severe cGVHD on DFS was seen. Intense immunosuppressive therapy, which has been correlated with severe cGVHD, may abrogate the effector cells of the GVL effect, and a lower risk of relapse can also be offset by increased NRM in severe cGVHD cases. Other authors have suggested that as relapse and NRM are competing events, there is a possibility that a part of the lower risk of relapse in patients with severe cGVHD may be due to competition between the risks of relapse and NRM rather than due to a true antileukemic activity. 4 Several transplant centers reported success with transplantation of T-cell-depleted (TCD) PBSCs with a low rate of GVHD. 25, 26 However, we pursue HSCT without TCD using unmanipulated haplo-HSCT protocols. High T-cell content of allografts without TCD potentially enhances the GVL effect compared with TCD haplo-HSCT, but the incidence of cGVHD is higher. In our study, the 3-year cumulative incidence of cGVHD was 460%; however, most of them were mild or moderate cGVHD, and the 3-year cumulative incidence of severe cGVHD was only 14.7%. We observed that mild or moderate cGVHD can improve the DFS after unmanipulated haplo-HSCT. In addition, we had observed that patients with mild or moderate cGVHD had health-related quality of life scores in keeping with population normative data, and their health-related quality of life scores were significantly higher than those of patients with severe cGVHD. 27 We were able to decrease the occurrence of severe cGVHD with our protocol, which included a combination of the G-PB/G-BM mixed harvest as the source of stem cell grafts as well as the addition of anti-thymocyte globulin to the conditioning regimen as prophylaxis for GVHD; however, efforts should be made to further reduce the severe cGVHD which gives no benefit to the patients after unmanipulated haplo-HSCT.
In our study, the NRM was not significantly higher in patients with cGVHD than that in those without cGVHD. A number of explanations may account for this finding. First, in our cohort, only 47 patients experienced severe cGVHD. Arai et al. 28 observed that the 2-year NRM was only 3% and 9% for mild and moderate cGVHD patients, respectively; however, the NRM reached a maximum of 32% for severe cGVHD patients (P o 0.0001). It is suggested that severe cGVHD was critical for the increased risk of NRM in cGVHD patients, and the relatively low incidence of severe cGVHD may account for the comparable NRM between the cGVHD and non-cGVHD groups in our study. Second, we confirmed that pre-HSCT comorbidities strongly predicted NRM after haplo-HSCT. 29 However, the ratio of patients with hematopoietic cell transplantation-specific comorbidity index scores of ⩾ 3 was comparable between the cGVHD and non-cGVHD groups, which suggested that the pre-HSCT comorbidity burden was comparable between the groups in this study.
In our study, we observed the impact of cGVHD on relapse in AML (CR1 or CR2) and MDS (RAEB1 or RAEB2) patients who received haplo-HSCT. In addition, our previous studies also observed that cGVHD was associated with a decreased relapse risk in acute leukemia patients who were in advanced stage at haplo-HSCT (CR3 or beyond, non-remission or relapse). Prophylactic DLI for patients without active GVHD or early relapse after transplantation was one of the most important methods for the prevention of relapse in those with advanced stage acute leukemia. Huang et al. 30 had reported that cGVHD after prophylactic DLI was associated with a lower relapse rate and higher probability of DFS in haplo-HSCT recipients. Thus, the cGVHD and GVL effects are highly correlated after prophylactic DLI in haplo-HSCT, which also demonstrated the susceptibility of acute leukemia to the GVL effect and was in keeping with the results in our study.
This study has certain limitations. Although it is a large study of unmanipulated haplo-HSCT in patients with AML and MDS, the number of cGVHD patients, particularly severe cGVHD patients, was relatively small and that might influence the accuracy of our results. Secondly, we only enrolled the haplo-HSCT recipients and our unmanipulated transplant protocol was distinct from what is observed in other haplo-HSCT performed with TCD, 25, 26 posttransplant CY, 31 or regulatory T-cell admixture. 32 Thus, it would be premature to derive conclusions regarding the association between severity of cGVHD and transplant outcomes in patients with AML and MDS. Additional large, multicenter studies may be able to further confirm our results and identify the association between cGVHD and clinical outcomes of HSCT.
In summary, our findings highlight the close relationship between cGVHD and the immune-mediated GVL effect in AML and MDS patients receiving unmanipulated haplo-HSCT. However, only mild or moderate cGVHD could be associated with a lower risk of relapse translating into improved DFS, whereas severe cGVHD had no impact on DFS. These findings highlight the need for improved prevention and treatment of severe cGVHD in patients receiving unmanipulated haplo-HSCT.
